REVIMMUNE Trademark

Trademark Overview

On Monday, November 19, 2018, a trademark application was filed for REVIMMUNE with the United States Patent and Trademark Office. The USPTO has given the REVIMMUNE trademark a serial number of 88983477. The federal status of this trademark filing is REGISTERED as of Tuesday, February 15, 2022. This trademark is owned by RevImmune, Inc.. The REVIMMUNE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development of biologicals and pharmaceuticals in the prevention and treatment of blood disease and cancer, viral and other infectious diseases, and the modulation and treatment of immune system related diseases and disorders
revimmune

General Information

Serial Number88983477
Word MarkREVIMMUNE
Filing DateMonday, November 19, 2018
Status700 - REGISTERED
Status DateTuesday, February 15, 2022
Registration Number6647373
Registration DateTuesday, February 15, 2022
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 9, 2019

Trademark Statements

Goods and ServicesResearch and development of biologicals and pharmaceuticals in the prevention and treatment of blood disease and cancer, viral and other infectious diseases, and the modulation and treatment of immune system related diseases and disorders

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, December 6, 2018
Primary Code042
First Use Anywhere DateMonday, November 30, 2015
First Use In Commerce DateMonday, November 30, 2015

Trademark Owner History

Party NameRevImmune, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressBethesda, MD 20814
Party NameRevImmune, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBethesda, MD 20814
Party NameRevImmune, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBethesda, MD 20814

Trademark Events

Event DateEvent Description
Tuesday, February 15, 2022REGISTERED-PRINCIPAL REGISTER
Wednesday, January 12, 2022NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, January 11, 2022ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, December 8, 2021STATEMENT OF USE PROCESSING COMPLETE
Monday, November 29, 2021USE AMENDMENT FILED
Wednesday, December 8, 2021DIVISIONAL PROCESSING COMPLETE
Monday, November 29, 2021DIVISIONAL REQUEST RECEIVED
Wednesday, December 8, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, November 29, 2021TEAS STATEMENT OF USE RECEIVED
Monday, November 29, 2021TEAS REQUEST TO DIVIDE RECEIVED
Thursday, May 27, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 25, 2021EXTENSION 4 GRANTED
Tuesday, May 25, 2021EXTENSION 4 FILED
Tuesday, May 25, 2021TEAS EXTENSION RECEIVED
Thursday, November 26, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 24, 2020EXTENSION 3 GRANTED
Tuesday, November 24, 2020EXTENSION 3 FILED
Tuesday, November 24, 2020TEAS EXTENSION RECEIVED
Tuesday, June 2, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, May 29, 2020EXTENSION 2 GRANTED
Friday, May 29, 2020EXTENSION 2 FILED
Friday, May 29, 2020TEAS EXTENSION RECEIVED
Wednesday, November 20, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 18, 2019EXTENSION 1 GRANTED
Monday, November 18, 2019EXTENSION 1 FILED
Monday, November 18, 2019TEAS EXTENSION RECEIVED
Tuesday, June 4, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 9, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 9, 2019PUBLISHED FOR OPPOSITION
Wednesday, March 20, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 26, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, February 22, 2019ASSIGNED TO EXAMINER
Thursday, December 6, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, November 22, 2018NEW APPLICATION ENTERED IN TRAM

Related Keywords

revimmune diseases treatment modulation infectious immune disorders related system other cancer